Impact of increased heart rate on clinical outcomes in hypertension: Implications for antihypertensive drug therapy

Drugs

Volumn 66, Issue 2, 2006, Pages 133-144

  Palatini, Paolo ^a   Benetos, Athanase ^b   Julius, Stevo ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; CILOBRADINE; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GUANFACINE; IMIDAZOLINE RECEPTOR AGONIST; ISOQUINOLINE DERIVATIVE; IVABRADINE; METHYLDOPA; MOXONIDINE; PHENYLALKYLAMINE; RILMENIDINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VALSARTAN; VASODILATOR AGENT; VERAPAMIL; ZETABRADINE;

ACUTE HEART INFARCTION; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTONOMIC NERVOUS SYSTEM; BLOOD FLOW; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG EFFECT; EPIDEMIOLOGICAL DATA; EXERCISE; HEART CONTRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART RATE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; IMPOTENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLISM; MORTALITY; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PULSE WAVE; REVIEW; RISK ASSESSMENT; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SMOKING CESSATION; SYMPATHETIC TONE; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE; VASOCONSTRICTION; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; EPIDEMIOLOGIC STUDIES; HUMANS; HYPERTENSION; TACHYCARDIA; TREATMENT OUTCOME;

EID: 32244432893     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200666020-00001     Document Type: Review

References (92)

1. Levy RL, White PD, Strod WD, et al. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945; 129: 585-8
2. Levy RL, Hillman CC, Stroud WD, et al. Transient hypertension: its significance in terms of later development of sustained hypertension and cardiovascular-renal diseases. JAMA 1944; 126: 829-33
3. Dyer A, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality findings in three Chicago Epidemiological Studies. Am J Epidemiol 1980; 112: 736-49
4. Kannel WB, Wilson P, Blair SN. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985; 109: 876-85
5. Gillmann MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 1993; 125: 1148-54
6. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens 1997; 15: 3-17
7. Jouven X, Desnos M, Guerot C, et al. Predicting sudden death in the population: the Paris Prospective Study 1. Circulation 1999; 99: 1978-83
8. Palatini P, Casiglia E, Julius S, et al. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999; 159: 585-92
9. Greenland P, Daviglus ML, Dyer AR, et al. Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality. Am J Epidemiol 1999; 149: 853-62
10. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999; 33: 44-52
11. Kristal-Boneh E, Silber H, Harari G, et al. The association of resting heart rate with cardiovascular, cancer and all-cause mortality: eight year follow-up of 3527 male Israeli employees (the CORDIS Study). Eur Heart J 2000; 21: 116-24
12. Thomas F, Bean K, Provost JC, et al. Combined effects of heart rate and pulse pressure on cardiovascular mortality according to age. J Hypertens 2001; 19: 863-9
13. Palatini P. Heart rate as a cardiovascular risk factor: do women differ from men? Ann Med 2001; 33: 213-21
14. Benetos A, Thomas F, Bean K, et al. Resting heart rate in older people: a predictor of survival to age 85. J Am Geriatr Soc 2003; 51: 284-5
15. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women: the Framingham Study. Arch Intern Med 1996; 156: 505-9
16. Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313-21
17. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-Up Study. Am Heart J 1991; 121: 172-7
18. Kannel WB, Kannel C, Paffenbarger RS, et al. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: 1489-94
19. Filipovsky J, Ducimetiere P, Safar ME. Prognostic significance of exercise blood pressure and heart rate in middle-aged men. Hypertension 1992; 20: 333-9
20. Sandvik L, Erikssen J, Ellestad M, et al. Heart rate increase and maximal heart rate during exercise as predictors of cardiovascular mortality: a 16-year follow-up study of 1960 healthy men. Coron Artery Dis 1995; 6: 667-79
21. Mensink GB, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997; 18: 1404-10
22. Reunanen A, Karjalainen J, Ristola P, et al. Heart rate and mortality. J Intern Med 2000; 247: 231-9
23. Fujiura Y, Adachi H, Tsuruta M, et al. Heart rate and mortality in a Japanese general population: an 18-year follow-up study. J Clin Epidemiol 2001; 54: 495-500
24. Jouven X, Zureik M, Desnos M, et al. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res 2001; 50: 373-8
25. Menotti A, Mulder I, Nissinen A, et al. Cardiovascular risk factors and 10-year all-cause mortality in elderly European male populations: the FINE study. Finland, Italy, Netherlands, Elderly. Eur Heart J 2001; 22: 573-9
26. Seccareccia F, Pannozzo F, Dima F, et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001; 91: 1258-63
27. Nilsson PM, Nilsson JA, Hedblad B, et al. Sleep disturbance in association with elevated pulse rate for prediction of mortality: consequences of mental strain? J Intern Med 2001; 250: 521-9
28. Chang M, Havlik RJ, Corti MC, et al. Relation of heart rate at rest and mortality in the Women's Health and Aging Study. Am J Cardiol 2003; 92: 1294-9
29. Perk G, Stessman J, Ginsberg G, et al. Sex differences in the effect of heart rate on mortality in the elderly. J Am Geriatr Soc 2003; 51: 1260-4
30. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens 2004; 17: 1005-10
31. Okamura T, Hayakawa T, Kadowaki T, et al. Resting heart rate and cause-specific death in a 16.5-year cohort study of the Japanese general population. Am Heart J 2004; 147: 1024-32
32. Hjalmarson A, Gilpin EA, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-53
33. Disegni E, Goldbourt U, Reicher-Reiss H, et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction: SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Clin Epidemiol 1995; 48: 1197-205
34. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995; 91: 1659-68
35. Copie X, Hnatkova K, Staunton A, et al. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction: results of a two-year follow-up study. J Am Coll Cardiol 1996; 27: 270-6
36. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22: 2085-103
37. Berton GS, Cordiano R, Palmieri R, et al. Heart rate during myocardial infarction: relationship with one-year global mortality in men and women. Can J Cardiol 2002; 18: 495-502
38. Abildstrom SZ, Jensen BT, Agner E, et al. Heart rate versus heart rate variability in risk prediction after myocardial infarction. J Cardiovasc Electrophysiol 2003; 14: 168-73
39. Kovar D, Cannon CP, Bentley JH, et al. Does initial and delayed heart rate predict mortality in patients with acute coronary syndromes? Clin Cardiol 2004; 27: 80-6
40. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111: 1777-83
41. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951-8
42. Thomas F, Rudnichi A, Bacri AM, et al. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37: 1256-61
43. Goldring W, Chassis H. Antihypertensive therapy: an appraisal. In: Ingelfienger J, Relman AS, Finland A, editors. Controversies in internal medicine. Philadelphia (PA): WB Saunders Publishers, 1966: 83
44. Erikssen J, Rodahl K. Resting heart rate in apparently healthy middle-aged men. Eur J Appl Physiol 1979; 42: 61-9
45. Berenson GS, Voors AW, Webber LS, et al. Racial differences of parameters associated with blood pressure levels in children: the Bogalusa Heart Study. Metabolism 1979; 28: 1218-28
46. Kim JR, Kiefe CL, Liu K, et al. Heart rate and subsequent blood pressure in young adults: the CARDIA Study. Hypertension 1999; 33: 640-6
47. Selby JV, Friedman GD, Quensenberry CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131: 1017-27
48. Paffenbarger RS, Thorne MC, Wing AL. Chronic disease in former college students: VIII. Characteristics in youth predisposing to hypertension in later years. Am J Epidemiol 1968; 88: 25-32
49. Mo R, Nordrehaug JE, Omvik P, et al. The Bergen Blood Pressure Study: prehypertensive changes in cardiac structure and function in offspring of hypertensive families. Blood Press 1995; 4: 16-22
50. Benetos A, Adamopoulos C, Bureau J-M, et al. Determinants of accelerated progression of arterial stiffness in normotensive and treated hypertensive subjects over a 6-year period. Circulation 2002; 105: 1202-7
51. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971; 44: 413-8
52. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11 Suppl. 1: 19-27
53. Palatini P, Casiglia E, Pauletto P, et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension 1997; 30: 1267-73
54. Bonaa KH, Arnesen E. Association between heart rate and atherogenic blood lipid fractions in a population: the Tromso Study. Circulation 1992; 86: 394-405
55. Julius S, Valentini M, Palatini P. Overweight and hypertension: a two-way street? Hypertension 2000; 35: 807-13
56. Valentini M, Julius S, Palatini P, et al. Attenuation of hemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens 2004; 22: 1999-2006
57. Bassiouny HS, Zarins CK, Kadowaki MH, et al. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 1994; 19: 426-34
58. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2
59. Kaplan JR, Manuck SB, Adams MR, et al. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987; 76: 1364-72
60. Mangoni AA, Mircoli L, Giannattasio C, et al. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 1996; 14: 897-901
61. Albaladejo P, Carusi A, Apartian A, et al. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res 2003; 40: 320-8
62. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82
63. Julius S. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res 1975; 36-37 Suppl. I: I199-207
64. Vogel CU, Wolpert C, Wehling M. How to measure heart rate? Eur J Clin Pharmacol 2004; 60: 461-6
65. Paffenbarger RS, Hyde RT, Wing AL, et al. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med 1986; 314: 605-13
66. Watts K, Jones TW, Davis EA, et al. Exercise training in obese children and adolescents: current concepts. Sports Med 2005; 35: 375-92
67. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993; 270: 1589-95
68. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-92
69. Palatini P. Treatment of tachycardia in hypertension: where do we stand now? Curr Hypertens Rev 2005; 1: 129-40
70. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43-49F
71. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55
72. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12
73. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
74. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 996-1003
75. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 869-71
76. Pollare T, Lithell H, Morlin C, et al. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7: 551-9
77. ALLHAT Officers and Coordinators, ALLHAT Collaborative Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
78. Jamerson KA, Julius S, Gudbrandsson T, et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21: 618-23
79. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995; 26: 143-9
80. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction: the Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol 1990; 66: 779-85
81. Messerli FH, Hansen JF, Gibson RS, et al. Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens 2001; 19: 977-82
82. Wellington K, Scott LJ. Azelnidipine. Drugs 2003; 63: 2613-21
83. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-8
84. Van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens 1997; 15 Suppl. 1: S3-8
85. Leu HB, Charng MJ, Ding PY. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension. Jpn Heart J 2004; 45: 623-35
86. Kaul CL, Ramarao P. Renin release and the sympathetic nervous system. Drugs Today (Barc) 2000; 36: 699-713
87. Palatini P, Mugellini A, Spagnuolo V, et al. Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Blood Press Monit 2004; 9: 91-7
88. Di Francesco D. The contribution of the 'pacemaker' current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991; 434: 23-40
89. Di Francesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757-65
90. Farinaro E, Stranges S, Guglielmucci G, et al. Heart rate as a risk factor in hypertensive individuals: the Italian TensioPulse Study. Nutr Metab Cardiovasc Dis 1999; 9: 196-202
91. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-53
92. Palatini P. Need for a revision of the normal limits of resting heart rate. Hypertension 1999; 33: 622-5